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Abstract: One of the most important obstacles in renal transplantation is the rejection
phenomenon. In spite of the developments in
medical technology and immunology, early
diagnosis of rejection and specific immunosuppression of the immune attack against the
graft have not yet been totally accomplished.
Lymphocyte cross-matching (LCM), a test to
detect the presence of preformed antibodies
in the donor against the recipient, is a practical and cheap method and is performed at
almost all renal transplantation centers
before transplantation. In this study, we

Departments of Akdeniz University Medical
School Transplantation team, Antalya-Turkey

Introduction
One of the most important obstacles in renal transplantation is the rejection phenomenon. In spite of the
developments in medical technology and immunology,
early diagnosis of rejection and specific immunosuppression of the immune attack aginst the graft have
not yet been totally accomplished. Current diagnosis of
allograft rejection is still mainly based on clinical and
biochemical data such as graft dysfunction and systemic manifestations (1). Lymphocyte cross-matching
(LCM), a test for detecting the presence of preformed
antibodies in the donor against the recipient, is a practical and cheap method and is performed at almost all
renal transplantation centers before transplantation.
In this study, we searched for the relation between
the formation of antidonor antibody and grafts loss in
renal transplant patients who did not have the antibody prior to transplantation.
Materials and Methods
Ninety-five patients who received renal transplant
from living related donors and in whom LCM was per-

searched for the relation between the posttransplant LCM status and graft survival.
LCM was positive in 7 patients and 5 lost
their grafts. On the other hand, of 88
patients, whose LCM remained negative, only
8 lost their grafts (p<0.05). In conclusion
LCM is a practical and cheap method for
detecting the presence of antidonor antibodies which closely relate with graft rejection.
Key Words: Lymphocyte Cross-match (LCM),
Renal transplantation Graft survival, DTT,
Rejection

formed at least postoperatively were included in the
study. Although it was planned to analyse all the
patients whose donors were alive retro- and prospectively every six months, this goal was not achieved in
most of the patients. LCM was done at four weeks
posttransplant period and then repeated at three or
six month intervals in the recently performed transplantations.
Criteria such as ABO blood group compatibility and
negative LCM were applied for donor selection and the
peroson with the best HLA matching was selected
among the potential donors.
The relation between LCM and graft loss was retrospectively evaluated. The clinician was informed
about the results of the LCM tests but no comments
about medical therapy of patients were made. Patients
who received anti-thymocyte globulin for the treatment of rejection were not included in the study
because of LCM positivity related to the therapy.
Lymphocyte cross-matching: Lymphocyte crossmatching, including autocrossmatch and dithiothreitol,
were performed as described previously (2). The evalluation was made semiquantitatively according to the
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percentage of dead cells (0-10%: negative, 10-20%:
1+, 25-35%: 2+, 35-50%: 3+, 50-80%:4+, 80100%: 5+)
Statistical Analysis: Comparisons between patient
groups were made using the chi-square test, and the
Fisher’s exact test where appropriate. A two-tailed P
value of <0.05 was considered statistically significant.
Results
LCM was positive 7 of 95 posttransplant patients.
In the patients in whom LCM was carried out 13
graft losses occurred in a follow-up period of three
years. The relationship between the LCM results and
graft loss is summarized in Table 1. It is found that
graft loss is significantly higher in patients with positive LCM (p>0.0005).
Graft loss occurred in five of the seven patients
three to twelve months after LCMs were found positive. In one of the two patients in whom graft loss
did not occur, LCM continued to be positive for three
months, and then became negative (it was tested
twice). The other case became negative after it was
found to be 2 (+) twice and 1 (+) once.
The relationship between the highest percent of
positivity in repeated tests and graft loss was not statistically significant (p=0.5254). This is shown in Table
2.
In only two patients, LCM positivity without DTT
changed to negative after DTT treatment. In the first
case who had 2+LCM, graft function was wellpreserved, but the second case having 3+LCM experienced severe rejection six months after having positive
LCM test.
Table 1.

The relationship between the LCM results and graft loss.
Graft Loss (+)

Graft Loss (-)

Total

5
8
13

2
80
82

7
88
95

LCM (+)
LCM (-)
Total

Table 2.

The relationship between the degree of positivity and graft
loss.

The highest percentage
of LCM

2+

3+

4+

Graft Loss (+)
Graft Loss (-)
Total

2
1
3

1
1
2

2
0
2
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Discussion
It is known that the possibility of hyperacute rejection is very high in the presence of performed antibodies in the recipient against the donor HLA antigens
(3-5). Therefore, a positive LCM Has been an important contraindication for transplantation except in a
few cases (6-8). Although the importance of the presence of donor organ directed antibodies is well-known,
there is little knowledge about the frequency and
importance of formation of antibodies in the posttransplant period and their roles in allograft rejection. It is
known that the allograft rejection is principally based
on T-cells except for the hyperacute rejection. In
experimental animals where there is no B cell function
and the transfer of rejection occurs by T cells only
supports this idea (1,9). Antibodies against graft antigens may slough away from the cell surface after they
attach to the antigens and these immnuocomplexes are
readily cleared by the reticuloendothelial system. Apart
from this, anti-anti-HLA antibodies, ie, antiidiotypic
antibodies may form in the host and these may block
the graft directed antibodies. As the antibody-antigen
complexes are rapidly cleared from the circulation,
they cannot be detected reliably in order to reflect the
real frequency and severity of the event (9-12). SuciuFoca (13-14) found the frequency of the formation of
the anti-HLA antibodies to be 23% and 28% in cadaveric heart and renal transplant patients, respectively,
for one year. In our study, this ratio was 7.2% for
one year. We think this lower incidence is due to the
difference of donor type (Cadaveric versus Livingrelated).
The formation of cytotoxic antibodies against the
donor lymphocytes in the posttransplant period is
shown to be closely related to rejection, but it is also
reported that the sensitivity of the test is considered
low and that its clinical use is limited, as the positivity
of the test continues even after the rejection attack
subsided (15-18). The clinical application of the test
has become less frequent since 1980. As in most of
the developed countries, the cadaveric donors are commonly used in many transplantation centres and so,
obtaining donor-cells is no longer practical. Besides,
more sensitive tests are being widely used to differentiate rejection from infection and cyclosporin toxicity.
In our cases, the occurrence of graft loss in 5 of 7
patients in whom LCM was positive and only in 8 of
the 88 patients who were negative, shows that this
test may be an important predictor of the risk of
graft loss. Since fine needle biobsy, serologic virological and flowcytomatric analysis techniques, which are
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commonly used for differentiation of rejection from
infection or drgu nephrotoxicity, are not generally
available in our country, we believe that the LCM test
still has a vulue in the early diagnosis of rejection.
We cannot comment whether this finding is associated with the type of relation of the recipient to the
donor or number of HLA mismatches, since the number of our LCM positive patients is low. But it is
interesting that in all of the 19 patients who had an
HLA mismatch of 0-2, LCM remained negative. There
is general agreement that the presence of donordirected IgM antibodies is not a contraindication for
transplantation (2,3,8). DTT showed that antibodies
were of IgM type. In only two of the patients. One of
these patients lost the graft; the other did not. The
limited number of patients hinder us from comment-

ing on the importance of IgM type antibodies in renal
transplantation but it does not seem to be a frequent
event.
Our method only shows the cytotoxic antibodies
capable of binding complement at a given concentration. Besides, we cannot deduce that the detected antibodies are directed to HLA antigens. They can be
directed to other alloantigens on the surface of Iymphocytes. However, in spite of all these limitations the
test we applied was found to be useful in predicting
the risk of graft loss. In conclusion, LCM is a cheap,
practial and rapid (results can be obtained in 3-4
hours) method of determining the risk of rejection in
our patients.
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